Stockscreener 앱 받기
12.64
2.51%
0.31
시간 외 거래:
12.90
0.26
+2.06%
전일 마감가:
$12.33
열려 있는:
$12.37
하루 거래량:
3.12M
Relative Volume:
1.79
시가총액:
$3.97B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-18.57
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+3.18%
1개월 성능:
+9.25%
6개월 성능:
+59.19%
1년 성능:
+64.37%
1일 변동 폭
$12.32
$12.71
1주일 범위
$12.12
$12.71
52주 변동 폭
$6.685
$12.71
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.64 | 3.88B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
122.76 | 53.87B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.83 | 45.71B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.32 | 34.49B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
507.00 | 22.00B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighStill a Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $12.69 - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com - Investing.com UK
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Decliners & Free High Accuracy Swing Entry Alerts - Улправда
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
Squarepoint Ops LLC Buys 420,398 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Esomeprazole Market Set to Witness Significant Growth - openPR.com
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Increased by BlackBarn Capital Partners LP - MarketBeat
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects - Sahm
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated at Barclays - MarketBeat
Amneal stock rises after FDA approves epinephrine injection By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care - Investing.com
Amneal stock rises after FDA approves epinephrine injection - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Epinephrine Injection, Expanding Its Injectables Portfolio for Emergency Care - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewswire
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal (Nasdaq: AMRX) gains FDA OK for epinephrine vials in $118M U.S. market - Stock Titan
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC - MarketBeat
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol - MSN
Amneal Pharmaceuticals Reports 'Substantial Clinical Benefit' from Crexont in Phase 4 Study - marketscreener.com
Amneal’s Parkinson’s drug shows positive interim results - Investing.com
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease - The Manila Times
Amneal announces positive interim phase 4 Elevate-Pd results with Crexont for Parkinson's disease - marketscreener.com
Will Amneal Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Amneal wins FDA approval for generic albuterol inhaler - World Aerosols
How Amneal Pharmaceuticals Inc. stock compares to market leaders2025 Top Gainers & Consistent Profit Alerts - Newser
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
AT&T sues generic drugmakers over alleged price-fixing scheme - Reuters
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Canada
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - simplywall.st
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment - geneonline.com
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05% - Ophthalmology Times
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - marketscreener.com
FDA approves Amneal’s generic albuterol inhaler - Investing.com
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - The Manila Times
Amneal to Participate in Upcoming Investor Conferences - The Manila Times
How institutional buying supports Amneal Pharmaceuticals Inc. stockWeekly Market Summary & Safe Entry Zone Identification - Newser
Amneal (Nasdaq: AMRX) adds 2nd Q4 2025 inhaler with FDA approval in $1.5B market - Stock Titan
Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05% - TipRanks
FDA approves Amneal’s generic Restasis for dry eye disease By Investing.com - Investing.com Australia
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
FDA approves Amneal’s generic Restasis for dry eye disease - Investing.com
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout - marketscreener.com
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - The Manila Times
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
12.55%
0.77%
자본화:
|
볼륨(24시간):